1.	Study to Assess Safety/Tolerability/Efficacy of Gefitinib Versus Docetaxel in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: D7913C00046, NCT00536107
2.	A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa Phase: Phase IV Type: Biomarker/Laboratory analysis, Natural history/Epidemiology Status: Active Age: Not specified Sponsor: Pharmaceutical / Industry Protocol IDs: 1839IL/0052 SubStudy, NCT01000740
3.	Iressa Follow-up Trial Phase: Phase III Type: Natural history/Epidemiology, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 1839IL/0555, D7913L00008, NCT00357734
4.	Randomized Gefitinib Trial Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: ONC-2008-001, NCT00807066
5.	Phase III Randomized Study of Prophylactic Cranial Radiotherapy in Patients With Advanced Non-Small Cell Lung Cancer That is Responsive to Gefitinib or Erlotinib Hydrochloride Phase: Phase III Type: Prevention, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: KROG-4-2008-0276, 4-2008-0276, NCT00955695
6.	Phase I/II Study of Gefitinib, Trastuzumab (Herceptin®), and Docetaxel in Patients With HER2/neu-Overexpressing Metastatic Adenocarcinoma of the Breast Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: CHNMC-03049, IRB 03049, ZENECA-1839US/0274, ZENECA-IRUSIRES0012, NCT00086957
7.	A Study Of Nasopharyngeal Carcinoma (NPC) Treated With Celecoxib And ZD1839 Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: NP01/07/03, NCT00212108
8.	Hydroxychloroquine and Gefitinib to Treat Lung Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 21 and over Sponsor: Other Protocol IDs: NS 01/03/08, NCT00809237
9.	Phase II Pilot Study of Neoadjuvant Gefitinib in Patients With Resectable Stage I-IIIA Non-Small Cell Lung Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: MCC-13922, ZENECA-IRUSIRES0256, MCC-IRB-102794, NCT00104728
10.	Phase II Study of Gefitinib in Patients With Recurrent or Metastatic Esophageal or Gastroesophageal Junction Cancer Phase: Phase II Type: Treatment Status: Active Age: Not specified Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: CASE-CCF-5538, ZENECA-1839IL/0234, NCT00268346
11.	Post-Operative Radiotherapy With Cisplatin Alone or in Combination With Iressa in Upper Aerodigestive Tract Carcinomas Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: GORTEC 2004-02, NCT00169221
12.	Phase II Study of Neoadjuvant Paclitaxel, Cisplatin, Gefitinib, and Radiotherapy Followed by Surgery and Adjuvant Gefitinib in Patients With Resectable, Locally Advanced Adenocarcinoma of the Esophagus or Gastroesophageal Junction Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 80 Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: JHOC-J0386, J0386, JHOC-04-02-20-03, ZENECA-IRUSIRES0304, NCT00493025
13.	Phase II Study of Neoadjuvant Gefitinib in Patients With Stage IIIA Nonsquamous Non-Small Cell Lung Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: YONSEI-4-2006-0136, 4-2006-0136, ZENECA-YONSEI-4-2006-0136, NCT00616499
14.	Study of Pemetrexed Versus Gefitinib in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Previously Received Platinum-Based Chemotherapy Without Epidermal Growth Factor Receptor (EGFR) Mutations Phase: Phase II Type: Treatment Status: Active Age: 18 to 80 Sponsor: Other Protocol IDs: C-TONG0806, NCT00891579
15.	Gefitinib 500mg Versus 250mg in Patients With Non-Small Cell Lung Cancer (NSCLC) With Stable Disease After a Month Treatment of Gefitinib 250mg Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: 08-JC-003, NCT01017679
16.	ZD1839 and Oral Irinotecan in Treating Young Patients With Refractory Solid Tumors Phase: Phase I Type: Treatment Status: Active Age: 21 and under Sponsor: NCI, Other Protocol IDs: POCPZD, IRUSIRES0181, NCT00132158
17.	ZD1839 With Hypofractionated Radiation Therapy With an Immobilization Device for Advanced Non Small Cell Lung Cancer Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 03C.225, NCT00328562
18.	Phase I Study of Iressa and CRT/IMRT in Chinese Patients With IIIB/IV NSCLC After Failure of Platinum-Based Chemotherapy Phase: Phase I Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: FDCA001, NCT00497250
19.	A Study of Serum Protein Profiling in Patients With Non-Small Cell Lung Cancer Treated With Gefitinib or Erlotinib Phase: No phase specified Type: Biomarker/Laboratory analysis Status: Active Age: 18 and over Sponsor: Other Protocol IDs: NS01/19/05, NCT00717847